CN104781673A - 定量方法、定量装置及定量用套件 - Google Patents
定量方法、定量装置及定量用套件 Download PDFInfo
- Publication number
- CN104781673A CN104781673A CN201380048822.0A CN201380048822A CN104781673A CN 104781673 A CN104781673 A CN 104781673A CN 201380048822 A CN201380048822 A CN 201380048822A CN 104781673 A CN104781673 A CN 104781673A
- Authority
- CN
- China
- Prior art keywords
- measured
- sample
- amount
- calibration curve
- sodium ion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 87
- 238000011002 quantification Methods 0.000 title claims abstract description 42
- 229910001415 sodium ion Inorganic materials 0.000 claims abstract description 166
- 238000011088 calibration curve Methods 0.000 claims abstract description 87
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims abstract description 78
- 238000006243 chemical reaction Methods 0.000 claims abstract description 72
- 241000239218 Limulus Species 0.000 claims abstract description 55
- 239000012086 standard solution Substances 0.000 claims abstract description 51
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 44
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 claims abstract description 36
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 claims abstract description 35
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 claims abstract description 35
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 claims abstract description 35
- 239000005089 Luciferase Substances 0.000 claims abstract description 31
- 108060001084 Luciferase Proteins 0.000 claims abstract description 31
- 239000002158 endotoxin Substances 0.000 claims description 110
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims description 80
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 80
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 33
- 229920002498 Beta-glucan Polymers 0.000 claims description 33
- 239000000243 solution Substances 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 20
- 230000003213 activating effect Effects 0.000 claims description 12
- 238000004445 quantitative analysis Methods 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 7
- 238000005259 measurement Methods 0.000 abstract description 104
- 239000000523 sample Substances 0.000 abstract description 91
- 230000035945 sensitivity Effects 0.000 abstract description 10
- 239000012472 biological sample Substances 0.000 abstract description 8
- 235000013305 food Nutrition 0.000 abstract description 8
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 62
- 238000004020 luminiscence type Methods 0.000 description 26
- 239000002904 solvent Substances 0.000 description 22
- 239000007864 aqueous solution Substances 0.000 description 18
- 239000008215 water for injection Substances 0.000 description 14
- 238000001223 reverse osmosis Methods 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 239000000758 substrate Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000001879 gelation Methods 0.000 description 8
- 230000002452 interceptive effect Effects 0.000 description 8
- 230000035484 reaction time Effects 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 238000004737 colorimetric analysis Methods 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000007865 diluting Methods 0.000 description 6
- 239000013067 intermediate product Substances 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 108010065152 Coagulase Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000000691 measurement method Methods 0.000 description 4
- 238000004879 turbidimetry Methods 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- LOTVQXNRIAEYCG-UHFFFAOYSA-N 3-hydroxy-2-(hydroxymethyl)-2-[hydroxymethyl(methyl)amino]propanoic acid Chemical compound OCN(C)C(CO)(CO)C(O)=O LOTVQXNRIAEYCG-UHFFFAOYSA-N 0.000 description 2
- 102000003712 Complement factor B Human genes 0.000 description 2
- 108090000056 Complement factor B Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N Tricine Natural products OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 2
- 235000011285 magnesium acetate Nutrition 0.000 description 2
- 239000011654 magnesium acetate Substances 0.000 description 2
- 229940069446 magnesium acetate Drugs 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 239000006179 pH buffering agent Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012480 LAL reagent Substances 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- BJNDPRQSSPYJKB-UHFFFAOYSA-N OCN(C)C(CO)(CO)C(O)=O.OCC(CO)(CO)NCC(O)=O Chemical compound OCN(C)C(CO)(CO)C(O)=O.OCC(CO)(CO)NCC(O)=O BJNDPRQSSPYJKB-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- RQVGAIADHNPSME-UHFFFAOYSA-N azinphos-ethyl Chemical compound C1=CC=C2C(=O)N(CSP(=S)(OCC)OCC)N=NC2=C1 RQVGAIADHNPSME-UHFFFAOYSA-N 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- YEIKGFFXYDKWAJ-UHFFFAOYSA-N ethyl hydrogen sulfate;2-piperazin-1-ylethanol Chemical compound CCOS(O)(=O)=O.OCCN1CCNCC1 YEIKGFFXYDKWAJ-UHFFFAOYSA-N 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000026676 system process Effects 0.000 description 1
- 206010052366 systemic mycosis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- -1 urine Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/008—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions for determining co-enzymes or co-factors, e.g. NAD, ATP
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/579—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving limulus lysate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/12—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar
- G01N2400/24—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar beta-D-Glucans, i.e. having beta 1,n (n=3,4,6) linkages between saccharide units, e.g. xanthan
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/50—Lipopolysaccharides; LPS
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012207268A JP5903017B2 (ja) | 2012-09-20 | 2012-09-20 | 定量方法、定量装置及び定量用キット |
| JP2012-207268 | 2012-09-20 | ||
| PCT/JP2013/075304 WO2014046183A1 (ja) | 2012-09-20 | 2013-09-19 | 定量方法、定量装置及び定量用キット |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104781673A true CN104781673A (zh) | 2015-07-15 |
Family
ID=50341487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380048822.0A Pending CN104781673A (zh) | 2012-09-20 | 2013-09-19 | 定量方法、定量装置及定量用套件 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20150225768A1 (enExample) |
| EP (1) | EP2899542A4 (enExample) |
| JP (1) | JP5903017B2 (enExample) |
| CN (1) | CN104781673A (enExample) |
| IN (1) | IN2015DN02992A (enExample) |
| WO (1) | WO2014046183A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109312328A (zh) * | 2016-06-21 | 2019-02-05 | 东亚Dkk株式会社 | 突变型甲虫荧光素酶、基因、重组载体、转化体，以及突变型甲虫荧光素酶的制备方法 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6789109B2 (ja) | 2016-12-28 | 2020-11-25 | 富士フイルム株式会社 | 血液分析方法及び血液検査キット |
| JP7397343B2 (ja) * | 2021-06-02 | 2023-12-13 | 東亜ディーケーケー株式会社 | エンドトキシンの測定方法 |
| JP7417117B2 (ja) * | 2021-06-21 | 2024-01-18 | 東亜ディーケーケー株式会社 | 発光分析装置及び発光分析装置の感度調整方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3944391A (en) * | 1974-12-27 | 1976-03-16 | Preventive Systems, Inc. | In vitro process for detecting endotoxin in a biological fluid |
| US5506113A (en) * | 1983-02-16 | 1996-04-09 | Unitika Ltd. | Measuring composition |
| JP2000131323A (ja) * | 1998-10-28 | 2000-05-12 | Fuji Photo Film Co Ltd | 調整管理血清 |
| CN101454448A (zh) * | 2006-07-07 | 2009-06-10 | 生化学工业株式会社 | 凝固酶原以及使用所述酶检测内毒素或(1→3)-β-D-葡聚糖的方法 |
| CN101855539A (zh) * | 2007-11-12 | 2010-10-06 | 国立大学法人广岛大学 | 内毒素浓度测定方法及浓度测定用试剂盒 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07110301A (ja) * | 1993-10-12 | 1995-04-25 | Toa Denpa Kogyo Kk | 細胞のａｔｐ量測定方法及び装置 |
| JPH1128099A (ja) * | 1997-05-12 | 1999-02-02 | Kikkoman Corp | 黄色ブドウ球菌の検出法 |
| EP0924220A3 (en) * | 1997-12-16 | 2000-04-26 | Wako Pure Chemical Industries, Ltd. | Inhibitor of the activation of beta-glucan recognition protein |
| WO2006080448A1 (ja) * | 2005-01-27 | 2006-08-03 | Seikagaku Corporation | リムルス測定用前処理剤 |
| JP2007064895A (ja) * | 2005-09-01 | 2007-03-15 | Wako Pure Chem Ind Ltd | 生体適用材料のエンドトキシン測定のための前処理方法及びエンドトキシンの測定方法 |
| US8492168B2 (en) * | 2006-04-18 | 2013-07-23 | Advanced Liquid Logic Inc. | Droplet-based affinity assays |
| JP5686308B2 (ja) * | 2009-02-20 | 2015-03-18 | 国立大学法人広島大学 | βグルカンの濃度測定方法および濃度測定用キット |
| WO2012029171A1 (ja) * | 2010-09-03 | 2012-03-08 | 興和株式会社 | 生物由来の生理活性物質の測定方法 |
-
2012
- 2012-09-20 JP JP2012207268A patent/JP5903017B2/ja not_active Expired - Fee Related
-
2013
- 2013-09-19 WO PCT/JP2013/075304 patent/WO2014046183A1/ja not_active Ceased
- 2013-09-19 CN CN201380048822.0A patent/CN104781673A/zh active Pending
- 2013-09-19 IN IN2992DEN2015 patent/IN2015DN02992A/en unknown
- 2013-09-19 EP EP13839625.4A patent/EP2899542A4/en not_active Withdrawn
- 2013-09-19 US US14/429,784 patent/US20150225768A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3944391A (en) * | 1974-12-27 | 1976-03-16 | Preventive Systems, Inc. | In vitro process for detecting endotoxin in a biological fluid |
| US5506113A (en) * | 1983-02-16 | 1996-04-09 | Unitika Ltd. | Measuring composition |
| JP2000131323A (ja) * | 1998-10-28 | 2000-05-12 | Fuji Photo Film Co Ltd | 調整管理血清 |
| CN101454448A (zh) * | 2006-07-07 | 2009-06-10 | 生化学工业株式会社 | 凝固酶原以及使用所述酶检测内毒素或(1→3)-β-D-葡聚糖的方法 |
| CN101855539A (zh) * | 2007-11-12 | 2010-10-06 | 国立大学法人广岛大学 | 内毒素浓度测定方法及浓度测定用试剂盒 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109312328A (zh) * | 2016-06-21 | 2019-02-05 | 东亚Dkk株式会社 | 突变型甲虫荧光素酶、基因、重组载体、转化体，以及突变型甲虫荧光素酶的制备方法 |
| CN109312328B (zh) * | 2016-06-21 | 2022-06-14 | 东亚Dkk株式会社 | 突变型甲虫荧光素酶、基因、重组载体、转化体，以及突变型甲虫荧光素酶的制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5903017B2 (ja) | 2016-04-13 |
| IN2015DN02992A (enExample) | 2015-09-25 |
| JP2014062785A (ja) | 2014-04-10 |
| WO2014046183A1 (ja) | 2014-03-27 |
| EP2899542A1 (en) | 2015-07-29 |
| US20150225768A1 (en) | 2015-08-13 |
| EP2899542A4 (en) | 2016-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6703569B2 (ja) | 定量的尿検査用乾燥試薬 | |
| ES2725426T3 (es) | Medios y procedimientos para calibración universal de pruebas anti-factor Xa | |
| CN104048931A (zh) | 一种肝素含量的检测方法 | |
| Min et al. | An AIEgens and exonuclease III aided quadratic amplification assay for detecting and cellular imaging of telomerase activity | |
| CN104781673A (zh) | 定量方法、定量装置及定量用套件 | |
| CN104232739A (zh) | 枸橼酸原料中细菌内毒素的检测方法 | |
| CN103760331B (zh) | 精浆联检试剂盒 | |
| CN101701962A (zh) | 一种血清镁标准物质 | |
| CN104166004B (zh) | 凝血因子ⅷ质控品制备方法 | |
| EP3146336B1 (en) | Storage device, system and method for determining the metabolic state of red blood cells and platelets | |
| CN102507466B (zh) | 一种改进的考马斯亮蓝测定蛋白质的光度法 | |
| US3888739A (en) | Reagents and methods for determining amylase concentrations | |
| CN104698159B (zh) | 一种内毒素含量的检测方法 | |
| CN100564538C (zh) | α-L-岩藻糖苷酶活性测定方法及α-L-岩藻糖苷酶诊断试剂 | |
| CN102703575B (zh) | 一种气泡上升法检测纤溶酶效价的方法 | |
| CN105445467B (zh) | 焦亚硫酸钠细菌内毒素的检测方法 | |
| Giampietro et al. | Decrease in plasma glucose concentration during storage at-20 degrees C. | |
| CN105158222B (zh) | 一种荧光定量的测量方法 | |
| Engel et al. | Bivalirudin Monitoring in Pediatric Ventricular Assist Device and Extracorporeal Membrane Oxygenation: Analysis of Single-Center Retrospective Cohort Data 2018–2022 | |
| CN107884402A (zh) | 过氧化氢一体化速测管及快速检测过氧化氢的方法 | |
| Zhou et al. | A new method for measuring total antioxidant capacity in urine using the iodine starch agar based on agar diffusion | |
| WO2016071887A1 (en) | Method to measure glycated hemoglobin | |
| CN1317564C (zh) | 一种目视检测尿液中无机磷的方法及其试剂盒 | |
| CN104458728A (zh) | 一种检测钠离子浓度的方法 | |
| CN109001455A (zh) | 一种肺泡灌洗液样本处理液及处理检测方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150715 |